BioCentury | Aug 9, 2010
Clinical News

FTA Bioscience, Pure Bioscience preclinical data

...silver dihydrogen citrate for 7 days produced significant mycological and clinical improvements vs. untreated controls. FTA Bioscience...
...exclusive, worldwide rights to the electrolytically generated source of stabilized ionic silver from Pure Bioscience. FTA Bioscience...
...INDs for multiple silver dihydrogen citrate-based products to treat foot and nail funguses next year. FTA Bioscience LLC...
BioCentury | Aug 9, 2010
Company News

FTA Bioscience, Pure Bioscience deal

...preclinical development. Pure Bioscience is eligible for milestones and royalties. Further terms were not disclosed. FTA Bioscience LLC...
BioCentury | Aug 10, 2009
Financial News

FTA Therapeutics LLC completes venture financing

FTA Therapeutics LLC , Pa. Business: Infectious Date completed: 7/30/09 Type: Venture financing Raised: Undisclosed Investor: Cleveland Clinic WIR Staff...
Items per page:
1 - 3 of 3
BioCentury | Aug 9, 2010
Clinical News

FTA Bioscience, Pure Bioscience preclinical data

...silver dihydrogen citrate for 7 days produced significant mycological and clinical improvements vs. untreated controls. FTA Bioscience...
...exclusive, worldwide rights to the electrolytically generated source of stabilized ionic silver from Pure Bioscience. FTA Bioscience...
...INDs for multiple silver dihydrogen citrate-based products to treat foot and nail funguses next year. FTA Bioscience LLC...
BioCentury | Aug 9, 2010
Company News

FTA Bioscience, Pure Bioscience deal

...preclinical development. Pure Bioscience is eligible for milestones and royalties. Further terms were not disclosed. FTA Bioscience LLC...
BioCentury | Aug 10, 2009
Financial News

FTA Therapeutics LLC completes venture financing

FTA Therapeutics LLC , Pa. Business: Infectious Date completed: 7/30/09 Type: Venture financing Raised: Undisclosed Investor: Cleveland Clinic WIR Staff...
Items per page:
1 - 3 of 3